Outcomes were compared on an intent-to-treat basis using propensity score matching. Median cardiopulmonary bypass time was 42 minutes longer for robotic than for complete sternotomy, 39 minutes longer than partial sternotomy, and 11 minutes longer than right mini-anterolateral thoracotomy (P < 0.0001). There were no in-hospital deaths in any group, and neurologic, pulmonary, and renal complications were similar among groups (P > 0.1). Inhibitors,research,lifescience,medical The robotic group had the lowest occurrences of atrial fibrillation and pleural effusion,

contributing to the shortest hospital stay (median 4.2 days); 1.0, 1.6, and 0.9 days shorter than for complete sternotomy, partial sternotomy, and right mini-anterolateral thoracotomy (all P < 0.001), respectively. Similar reductions in length of stay were seen at the University of Pennsylvania in a comparison of 39 patients who underwent sternotomy and mitral valve repair, or replacement, with 26 patients who underwent robotically assisted mitral valve repair or replacement.13 Patients who underwent Inhibitors,research,lifescience,medical robotic-assisted surgery experienced shorter mean duration of postoperative hospitalization (7.1

versus 10.6 days; P = 0.04), despite longer cross-clamp Inhibitors,research,lifescience,medical and bypass times (110 versus 151 minutes, P = 0.0015; 162 versus 239 minutes, P = 0.001, respectively). Mean packed red blood cell transfusion was also lower among patients who underwent robotic-assisted mitral valve surgery (5.0 versus 2.8 units, P = 0.04). Today, most robot-assisted mitral valve repairs are accomplished either through a 3–4-cm right anterolateral mini-thoracotomy or a 2-cm lateral Inhibitors,research,lifescience,medical working port. The articulating EndoWrist™ (Intuitive Surgical, Sunnyvale, CA, USA) instruments and dynamic left atrial retractor allow console surgeons to employ Carpentier’s and others’ “toolbox” of repair techniques. Our institution has performed over

800 robotic mitral valve repairs. Results have been published for the first 540 patients.14 Of these, Inhibitors,research,lifescience,medical 454 patients underwent a lone mitral repair, and 86 had Methisazone a Selleckchem AR-A014418 concomitant atrial fibrillation ablation. The average cardiopulmonary bypass and cross-clamp times were 153 and 116 minutes, respectively, in the lone mitral repair patients. The group operative mortality was 0.4%. The mean follow-up period was 351 days (15–946 days), and 2.9% of patients required a reoperation for a failed repair. The cardiopulmonary bypass and arrest times have improved with on-going experience. In the first FDA trial, the average cross-clamp time was 150 minutes.10 In the second multicenter FDA trial, the average cross-clamp time fell to 126 minutes, and there was little variation in operative time between centers.11 We use topographic valve models, derived from intra-operative high-quality three-dimensional transesophageal echocardiography images to plan a successful repair.